

**Abstract**

**Treatment of Neuropathy**

This invention relates to the use of cyclic guanosine 3', 5'-monophosphate  
5 phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the  
compound sildenafil, for the treatment of neuropathy, including in particular the  
treatment of diabetic neuropathy.